Nav: Home

NSAIDs modulate biomarker panel for esophageal adenocarcinoma

February 26, 2007

Nonsteroidal anti-inflammatory drugs may give some protection against esophageal adenocarcinoma developing from its premalignant state, Barrett's esophagus.

Genetic abnormalities are common in many human cancers and their precursors, including esophageal adenocarcinoma and Barrett's esophagus. Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have been proposed as possible chemoprevention against esophageal adenocarcinoma and Barrett's esophagus.

A study of 243 patients with Barrett's esophagus followed up for 10 years by Patricia Galipeau and colleagues from the Fred Hutchinson Cancer Research Center, Seattle looked at various genetic changes, including specific mutations and variations in the total amount of DNA present. They assessed whether each genetic abnormality was associated with the risk of developing esophageal adenocarcinoma, and whether the risk was altered in patients who had taken aspirin or other NSAIDs.

The researchers found that over 10 y, all abnormalities, except two, contributed significantly to the risk of developing esophageal adenocarcinoma. A panel of genetic abnormalities was the best predictor of developing esophageal adenocarcinoma; over 10 years patients with no baseline abnormality had a 12% cumulative incidence of esophageal adenocarcinoma, whereas patients with the full panel of genetic abnormalities had a 79% incidence. In patients with none, one, two, or three baseline genetic abnormalities, the risk of developing esophageal adenocarcinoma was significantly reduced among users of NSAIDs compared to nonusers, with the strongest protective effect being seen in participants with multiple genetic abnormalities.

These findings may have implications for the treatment of patient with Barrett's esophagus, but especially since this is an observational study, and not a randomised trial, it will need to be confirmed in other groups of patients.
-end-
EMBARGO: MONDAY, 26 February, 5 P.M. PDT

Everything published by PLoS Medicine is Open Access: freely available for anyone to read, download, redistribute and otherwise use, as long as the authorship is properly attributed.

Please mention PLoS Medicine in your report and use the links below to take your readers straight to the online articles:

Citation: Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, et al. (2007) NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4(2): e67.

PLEASE ADD THE LINK TO THE PUBLISHED ARTICLE IN ONLINE
VERSIONS OF YOUR REPORT: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0040067

PRESS-ONLY PREVIEW OF THE ARTICLE: http://www.plos.org/press/plme-04-02-galipeau.pdf

CONTACT:
Patricia Galipeau
Fred Hutchinson Cancer Research Center
Human Biology
1100 Fairview Ave N C1-157
PO BOX 19024
Seattle, WA 98109 United States of America
+1 206-667-4615
+1 206-667-6132 (fax)
pgal@fhcrc.org

PLOS

Related Aspirin Articles:

Switching to aspirin/clopidogrel following 1 month of new P2Y12 inhibitor/aspirin post-ACS
Paris, France: Switching to a fixed-dose combination of aspirin plus clopidogrel after one month of potent dual antiplatelet therapy (DAPT) with a new P2Y12 inhibitor plus aspirin following an acute coronary syndrome (ACS) treated with a percutaneous coronary intervention (PCI) is associated with reduced risk of bleeding complications with no increase in ischaemic events, showed results from a study reported at EuroPCR 2017.
An alternative theory on how aspirin may thwart cancer
Many studies have pointed to a role for aspirin in cancer prevention.
New 'Aspirin-Guide' app for clinicians helps personalize decisions about aspirin use
To help clinicians and patients make informed decisions about aspirin use, researchers at Brigham and Women's Hospital have developed a new, free, mobile app, 'Aspirin-Guide' that calculates both the CVD risk score and the bleeding risk score for the individual patient, and helps clinicians decide which patients are appropriate candidates for the use of low-dose aspirin.
Aspirin may help prevent bile duct cancer
Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study.
Taking aspirin could increase cancer survival by 20 percent
Patients receiving cancer treatment could increase their chance of survival by up to 20 percent and help stop their cancer from spreading by taking a low dose of aspirin, new research suggests.
More Aspirin News and Aspirin Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...